Close

Clinical Development Success Rates

 

 

The Biotechnology Innovation Organization (BIO) has released the largest ever study of clinical development success rates, with a focus on the advantages of using biomarkers in clinical trials.  

 

Some of the conclusions: 

  • Clinical trial programs that used selection biomarkers saw an overall likelihood of approval (LOA) from Phase I of 25.9%, compared to 8.4% when no selection biomarkers were used.

  • Oncology drugs were approved the fastest of all 14 disease areas.

 

Read the study: http://bit.ly/22o5TGf

 

 

 

 

 

 

 

 

 

Share on facebook
Partager sur Facebook
Share on linkedin
Partager sur Linkedin